Aryx Therapeutics (ARYX) 0.0106 $ARYX
SarlaFlex Inc. Closes $13 Million in NMTC Financing for New U.S. Facility
Marketwire - Fri Jan 17, 8:35AM CST
SarlaFlex Inc. has secured $13 million in New Markets Tax Credit (NMTC) allocation from Los Angeles-based National New Markets Fund, LLC (NNMF) to redevelop a manufacturing facility in rural South Carolina into the company's first U.S. based yarn and thread plant. U.S. Bank serves as the tax credit investor, capitalizing the allocation.
Biomarker Partnering Terms and Agreements: 2013 Report is Out Now for Review
M2 - Mon Nov 25, 10:10AM CST
Research and Markets (http://www.researchandmarkets.com/research/fn742d/biomarker) has announced the addition of the "Biomarker Partnering Terms and Agreements" report to their offering. This report contains over 800 links to online copies of actual biomarker deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. The initial chapters of this report provide an orientation of biomarker dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in biomarker dealmaking since 2007, including details of average headline, upfront, milestone and royalty terms. Chapter 3 provides a review of the leading biomarker deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract. Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of biomarker deals as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand. Chapter 5 provides a comprehensive and detailed review of biomarker partnering deals signed and announced since January 2007, where a contract document is available in the public domain. The chapter is organized by stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. Chapter 6 provides a comprehensive and detailed review of biomarker partnering deals signed and announced since January 2007. The chapter is organized by specific diagnpstics technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. In addition, a comprehensive appendix is provided organized by biomarker partnering company A-Z , stage of development, deal type, therapy area, deal type definitions and biomarker partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. Companies Mentioned: - ARYx Therapeutics - Biogen Idec - Boehringer Ingelheim - Bristol-Myers Squibb - Cardiome Pharma - Daiichi Sankyo - Dynavax Technologies - Eisai - Eli Lilly - Gilead Sciences - GlaxoSmithKline - GTx - Hyperion Therapeutics - Inspire Pharmaceuticals - Janssen Research & Development - KaloBios Pharmaceuticals - La Jolla Pharmaceutical - Merck and Co - Novartis Consumer Health - Novo Nordisk - OncoGenex Pharmaceuticals - Pfizer - PhotoMedex - Procter & Gamble - Sigma-Tau - Solvay - Transcept Pharmaceuticals - Ucyclyd Pharma - Valeant Pharmaceuticals - Wyeth - Xenoport - Zogenix For more information visit http://www.researchandmarkets.com/research/fn742d/biomarker About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics - 2013: Fully Revised and Updated
M2 - Mon Nov 18, 5:29AM CST
Research and Markets (http://www.researchandmarkets.com/research/vdd85f/copromotion_and) has announced the addition of the "Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics" report to their offering. The Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the co-promotion and co-marketing partnering agreements entered into by the worlds leading healthcare companies. Revised and updated 9th edition, includes: - Trends in co-promotion and co-marketing deals - Co-promotion and co-marketing agreement structure - Co-promotion and co-marketing contract documents - Top co-promotion deals by value - Top co-marketing deals by value - Most active co-promotion dealmakers - Most active co-marketing dealmakers This report provides details of the latest co-promotion and co-marketing agreements announced in the pharmaceutical, biotechnology and diagnostic sectors. Fully revised and updated, the report provides details of co-promotion and co-marketing agreements from 2007 to end of Sep 2013. This report contains over 850 links to online copies of actual co-promotion and co-marketing contract documents as submitted to the Securities Exchange Commission by biopharma companies and their partners. Companies Mentioned: - Abbott Japan - Ariad Pharmaceuticals - ArQule - Array Biopharma - ARYx Therapeutics - Astellas Pharma - Boehringer Ingelheim - Bristol-Myers Squibb - Cardiome Pharma - Celgene - Dyax - Dynavax Technologies - Eisai - Eli Lilly - Enanta Pharmaceuticals - Endo Pharmaceuticals - Exelixis - Facet Biotechnology - Forest Laboratories - Genentech - GlaxoSmithKline - Hyperion Therapeutics - Ironwood Pharmaceuticals - Janssen Research & Development - KaloBios Pharmaceuticals - La Jolla Pharmaceutical - Macrogenics - MAP Pharmaceuticals - Maxygen - Merck and Co - Novartis - Nycomed - OncoGenex Pharmaceuticals - Pfizer - Procter & Gamble Pharmaceuticals - Purdue Pharma - Regeneron Pharmaceuticals - Salix Pharmaceuticals - Schering-Plough - Solvay - TAP Pharmaceutical - Teva Pharmaceuticals - Tibotec - Transcept Pharmaceuticals - Ucyclyd Pharma - Valeant Pharmaceuticals - Watson Pharmaceuticals - Wyeth - Xenoport - ZymoGenetics For more information visit http://www.researchandmarkets.com/research/vd...motion_and About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Functional (Non Ulcer) Dyspepsia - Pipeline Review, H2 2012
M2 - Thu Jul 11, 11:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rqxvxn/functional_non) has announced the addition of the "Functional (Non Ulcer) Dyspepsia - Pipeline Review, H2 2012" report to their offering. This report provides an overview of the Functional (Non Ulcer) Dyspepsia therapeutic pipeline. This report provides information on the therapeutic development for Functional (Non Ulcer) Dyspepsia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Functional (Non Ulcer) Dyspepsia. 'Functional (Non Ulcer) Dyspepsia - Pipeline Review, H2 2012' is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team of experts. Key Topics Covered: List of Tables List of Figures Introduction REPORT COVERA
SarlaFlex Inc. Closes $13 Million in NMTC Financing for New U.S. Facility
Marketwire - Fri Jan 17, 8:35AM CST
SarlaFlex Inc. has secured $13 million in New Markets Tax Credit (NMTC) allocation from Los Angeles-based National New Markets Fund, LLC (NNMF) to redevelop a manufacturing facility in rural South Carolina into the company's first U.S. based yarn and thread plant. U.S. Bank serves as the tax credit investor, capitalizing the allocation.
Biomarker Partnering Terms and Agreements: 2013 Report is Out Now for Review
M2 - Mon Nov 25, 10:10AM CST
Research and Markets (http://www.researchandmarkets.com/research/fn742d/biomarker) has announced the addition of the "Biomarker Partnering Terms and Agreements" report to their offering. This report contains over 800 links to online copies of actual biomarker deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. The initial chapters of this report provide an orientation of biomarker dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in biomarker dealmaking since 2007, including details of average headline, upfront, milestone and royalty terms. Chapter 3 provides a review of the leading biomarker deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract. Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of biomarker deals as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand. Chapter 5 provides a comprehensive and detailed review of biomarker partnering deals signed and announced since January 2007, where a contract document is available in the public domain. The chapter is organized by stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. Chapter 6 provides a comprehensive and detailed review of biomarker partnering deals signed and announced since January 2007. The chapter is organized by specific diagnpstics technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. In addition, a comprehensive appendix is provided organized by biomarker partnering company A-Z , stage of development, deal type, therapy area, deal type definitions and biomarker partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. Companies Mentioned: - ARYx Therapeutics - Biogen Idec - Boehringer Ingelheim - Bristol-Myers Squibb - Cardiome Pharma - Daiichi Sankyo - Dynavax Technologies - Eisai - Eli Lilly - Gilead Sciences - GlaxoSmithKline - GTx - Hyperion Therapeutics - Inspire Pharmaceuticals - Janssen Research & Development - KaloBios Pharmaceuticals - La Jolla Pharmaceutical - Merck and Co - Novartis Consumer Health - Novo Nordisk - OncoGenex Pharmaceuticals - Pfizer - PhotoMedex - Procter & Gamble - Sigma-Tau - Solvay - Transcept Pharmaceuticals - Ucyclyd Pharma - Valeant Pharmaceuticals - Wyeth - Xenoport - Zogenix For more information visit http://www.researchandmarkets.com/research/fn742d/biomarker About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics - 2013: Fully Revised and Updated
M2 - Mon Nov 18, 5:29AM CST
Research and Markets (http://www.researchandmarkets.com/research/vdd85f/copromotion_and) has announced the addition of the "Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics" report to their offering. The Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the co-promotion and co-marketing partnering agreements entered into by the worlds leading healthcare companies. Revised and updated 9th edition, includes: - Trends in co-promotion and co-marketing deals - Co-promotion and co-marketing agreement structure - Co-promotion and co-marketing contract documents - Top co-promotion deals by value - Top co-marketing deals by value - Most active co-promotion dealmakers - Most active co-marketing dealmakers This report provides details of the latest co-promotion and co-marketing agreements announced in the pharmaceutical, biotechnology and diagnostic sectors. Fully revised and updated, the report provides details of co-promotion and co-marketing agreements from 2007 to end of Sep 2013. This report contains over 850 links to online copies of actual co-promotion and co-marketing contract documents as submitted to the Securities Exchange Commission by biopharma companies and their partners. Companies Mentioned: - Abbott Japan - Ariad Pharmaceuticals - ArQule - Array Biopharma - ARYx Therapeutics - Astellas Pharma - Boehringer Ingelheim - Bristol-Myers Squibb - Cardiome Pharma - Celgene - Dyax - Dynavax Technologies - Eisai - Eli Lilly - Enanta Pharmaceuticals - Endo Pharmaceuticals - Exelixis - Facet Biotechnology - Forest Laboratories - Genentech - GlaxoSmithKline - Hyperion Therapeutics - Ironwood Pharmaceuticals - Janssen Research & Development - KaloBios Pharmaceuticals - La Jolla Pharmaceutical - Macrogenics - MAP Pharmaceuticals - Maxygen - Merck and Co - Novartis - Nycomed - OncoGenex Pharmaceuticals - Pfizer - Procter & Gamble Pharmaceuticals - Purdue Pharma - Regeneron Pharmaceuticals - Salix Pharmaceuticals - Schering-Plough - Solvay - TAP Pharmaceutical - Teva Pharmaceuticals - Tibotec - Transcept Pharmaceuticals - Ucyclyd Pharma - Valeant Pharmaceuticals - Watson Pharmaceuticals - Wyeth - Xenoport - ZymoGenetics For more information visit http://www.researchandmarkets.com/research/vd...motion_and About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Functional (Non Ulcer) Dyspepsia - Pipeline Review, H2 2012
M2 - Thu Jul 11, 11:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rqxvxn/functional_non) has announced the addition of the "Functional (Non Ulcer) Dyspepsia - Pipeline Review, H2 2012" report to their offering. This report provides an overview of the Functional (Non Ulcer) Dyspepsia therapeutic pipeline. This report provides information on the therapeutic development for Functional (Non Ulcer) Dyspepsia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Functional (Non Ulcer) Dyspepsia. 'Functional (Non Ulcer) Dyspepsia - Pipeline Review, H2 2012' is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team of experts. Key Topics Covered: List of Tables List of Figures Introduction REPORT COVERA
